MX355836B - Composicion que comprende compuestos tetraciclicos. - Google Patents
Composicion que comprende compuestos tetraciclicos.Info
- Publication number
- MX355836B MX355836B MX2013001989A MX2013001989A MX355836B MX 355836 B MX355836 B MX 355836B MX 2013001989 A MX2013001989 A MX 2013001989A MX 2013001989 A MX2013001989 A MX 2013001989A MX 355836 B MX355836 B MX 355836B
- Authority
- MX
- Mexico
- Prior art keywords
- tetracyclic compound
- composition containing
- useful
- water
- absorbability
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición que comprende la sustancia representada por Fórmula (I), un vehículo aceptable farmacéuticamente, y un coadyuvante de disolución, útil para mejorar la solubilidad, la absorción oral y/o la absorción en sangre de compuestos tetracíclicos con un actividad inhibidora de ALK poco solubles en agua o insolubles en agua, que son útiles como agentes profilácticos y/o terapéuticos para tratar cáncer, depresión, y trastornos de la función cognitiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010185385 | 2010-08-20 | ||
PCT/JP2011/068735 WO2012023597A1 (ja) | 2010-08-20 | 2011-08-19 | 4環性化合物を含む組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013001989A MX2013001989A (es) | 2013-05-28 |
MX355836B true MX355836B (es) | 2018-05-02 |
Family
ID=45605249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001989A MX355836B (es) | 2010-08-20 | 2011-08-19 | Composicion que comprende compuestos tetraciclicos. |
Country Status (21)
Country | Link |
---|---|
US (4) | US9365514B2 (es) |
EP (2) | EP2606886B1 (es) |
JP (1) | JP4918630B1 (es) |
KR (1) | KR101362589B1 (es) |
CN (1) | CN103052386B (es) |
AR (2) | AR083246A1 (es) |
AU (1) | AU2011291708B2 (es) |
BR (1) | BR112013003879B1 (es) |
CA (1) | CA2808210C (es) |
ES (1) | ES2769550T3 (es) |
HK (1) | HK1179878A1 (es) |
IL (1) | IL223892B (es) |
MX (1) | MX355836B (es) |
MY (1) | MY160110A (es) |
NZ (1) | NZ608312A (es) |
PL (1) | PL2606886T3 (es) |
RU (1) | RU2573392C3 (es) |
SG (1) | SG187614A1 (es) |
TW (1) | TWI526441B (es) |
WO (1) | WO2012023597A1 (es) |
ZA (1) | ZA201300020B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4588121B1 (ja) * | 2009-06-10 | 2010-11-24 | 中外製薬株式会社 | 4環性化合物 |
AU2011291708B2 (en) | 2010-08-20 | 2015-03-19 | Chugai Seiyaku Kabushiki Kaisha | Composition containing tetracyclic compound |
DK2902029T3 (en) | 2012-09-25 | 2018-10-29 | Chugai Pharmaceutical Co Ltd | RET INHIBITOR |
CN104109168B (zh) * | 2013-04-20 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CN104177332A (zh) * | 2013-05-20 | 2014-12-03 | 中国科学院上海药物研究所 | 酰胺基取代的吲哚并萘酮衍生物及其医药用途 |
CN104177342B (zh) * | 2013-05-21 | 2018-01-05 | 中国科学院上海药物研究所 | 杂环基取代的吲哚并萘酮衍生物及其医药用途 |
WO2014190949A1 (zh) * | 2013-06-01 | 2014-12-04 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
EP3135287A4 (en) * | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CN106458967A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 四环化合物的新结晶 |
RU2720680C2 (ru) | 2014-06-18 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция, содержащая неионные сурфактанты |
TWI765410B (zh) * | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體的用途 |
CN105566307B (zh) * | 2014-10-11 | 2019-04-23 | 中国科学院上海药物研究所 | 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途 |
CN104402862B (zh) * | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | 艾立替尼的制备方法 |
RU2740261C2 (ru) | 2015-01-16 | 2021-01-12 | Чугаи Сейяку Кабусики Кайся | Комбинированное лекарственное средство |
CN105777710B (zh) * | 2016-04-05 | 2018-09-04 | 湖南欧亚药业有限公司 | 一种艾乐替尼的合成方法 |
CN106518842A (zh) * | 2016-09-20 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种艾乐替尼的制备方法 |
US10781208B2 (en) * | 2016-11-18 | 2020-09-22 | The Regents Of The University Of Michigan | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors |
CN106928125A (zh) * | 2017-04-21 | 2017-07-07 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼中间体的制备方法 |
CN107129488A (zh) * | 2017-04-21 | 2017-09-05 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
CN107011245A (zh) * | 2017-04-21 | 2017-08-04 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼中间体的制备方法 |
CN106892860B (zh) * | 2017-04-21 | 2019-08-02 | 湖南博奥德药业有限公司 | 一种艾乐替尼中间体的制备方法 |
CN106892861A (zh) * | 2017-04-21 | 2017-06-27 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼中间体的制备方法 |
WO2019008520A1 (en) | 2017-07-05 | 2019-01-10 | Fresenius Kabi Oncology Limited | PROCESS FOR THE PREPARATION OF ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
JP7054134B2 (ja) * | 2017-12-07 | 2022-04-13 | 国立大学法人京都大学 | ベンゾ[b]カルバゾール化合物及びそれを用いたイメージング |
EP3815688B1 (en) * | 2018-06-29 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing poorly-soluble basic medicine |
AR116113A1 (es) | 2018-09-04 | 2021-03-31 | Chugai Pharmaceutical Co Ltd | Método para fabricar un compuesto tetracíclico |
EP3556754A1 (en) | 2018-12-07 | 2019-10-23 | Fresenius Kabi iPSUM S.r.l. | Process for the preparation of alectinib |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
AR121187A1 (es) * | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP7419572B2 (ja) | 2021-01-29 | 2024-01-22 | 中外製薬株式会社 | 小児がん治療用医薬組成物 |
JPWO2023074785A1 (es) | 2021-10-28 | 2023-05-04 | ||
WO2023161233A1 (en) * | 2022-02-22 | 2023-08-31 | Synthon B.V. | Solid forms of alectinib and alectinib salts |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
JPH0667840B2 (ja) | 1988-11-30 | 1994-08-31 | 萬有製薬株式会社 | Nb―818の易吸収性製剤 |
JPH0892090A (ja) * | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
DE69505470T2 (de) | 1994-08-04 | 1999-05-12 | F. Hoffmann-La Roche Ag, Basel | Pyrrolocarbazol |
JPH09202728A (ja) | 1995-12-11 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | 固形製剤 |
CA2252701C (en) | 1996-05-01 | 2003-10-28 | Mississippi State University | Halo-substituted protein kinase c inhibitors |
EP1178988B1 (en) | 1999-05-14 | 2007-02-28 | The Australian National University | Compounds and therapeutic methods |
WO2002043704A1 (en) * | 2000-12-01 | 2002-06-06 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in solubility or oral absorbability |
US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
EP1603567A4 (en) | 2003-02-28 | 2006-10-18 | Inotek Pharmaceuticals Corp | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF |
DK1454992T3 (da) | 2003-03-07 | 2006-10-02 | Ist Naz Stud Cura Dei Tumori | Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
US20070060595A1 (en) * | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
AU2004295061B2 (en) | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
JP4927704B2 (ja) | 2004-03-19 | 2012-05-09 | シュペーデル・エクスペリメンタ・アーゲー | 有機化合物 |
US7973061B2 (en) | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
PL1786785T3 (pl) | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
CN101304993A (zh) | 2005-11-07 | 2008-11-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
PT1963302E (pt) * | 2005-12-05 | 2013-04-09 | Pfizer Prod Inc | Polimorfos de um inibidor de c-met/hgfr |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
MX2009002563A (es) | 2006-09-14 | 2009-03-20 | Astellas Pharma Inc | Tableta de desintegracion oral y proceso para la produccion de la misma. |
CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
EP2222647B1 (en) * | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
PT2176231T (pt) | 2007-07-20 | 2016-12-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos activos como inibidores de quinases |
CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
US20090214648A1 (en) | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
KR20120034639A (ko) | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
JP4588121B1 (ja) | 2009-06-10 | 2010-11-24 | 中外製薬株式会社 | 4環性化合物 |
AU2011291708B2 (en) | 2010-08-20 | 2015-03-19 | Chugai Seiyaku Kabushiki Kaisha | Composition containing tetracyclic compound |
TWI564008B (zh) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
JP5006987B2 (ja) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | 4環性化合物を含む医薬 |
DK2902029T3 (en) | 2012-09-25 | 2018-10-29 | Chugai Pharmaceutical Co Ltd | RET INHIBITOR |
WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
EP3135287A4 (en) | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CN106458967A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 四环化合物的新结晶 |
RU2720680C2 (ru) | 2014-06-18 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция, содержащая неионные сурфактанты |
TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體的用途 |
-
2011
- 2011-08-19 AU AU2011291708A patent/AU2011291708B2/en active Active
- 2011-08-19 TW TW100129707A patent/TWI526441B/zh active
- 2011-08-19 WO PCT/JP2011/068735 patent/WO2012023597A1/ja active Application Filing
- 2011-08-19 CA CA2808210A patent/CA2808210C/en active Active
- 2011-08-19 BR BR112013003879-9A patent/BR112013003879B1/pt active IP Right Grant
- 2011-08-19 SG SG2013006408A patent/SG187614A1/en unknown
- 2011-08-19 RU RU2013112011A patent/RU2573392C3/ru active Protection Beyond IP Right Term
- 2011-08-19 MX MX2013001989A patent/MX355836B/es active IP Right Grant
- 2011-08-19 EP EP11818237.7A patent/EP2606886B1/en active Active
- 2011-08-19 KR KR1020137006780A patent/KR101362589B1/ko active Protection Beyond IP Right Term
- 2011-08-19 US US13/816,804 patent/US9365514B2/en active Active
- 2011-08-19 JP JP2011536692A patent/JP4918630B1/ja active Active
- 2011-08-19 CN CN201180040147.8A patent/CN103052386B/zh active Active
- 2011-08-19 NZ NZ608312A patent/NZ608312A/en unknown
- 2011-08-19 EP EP20150229.1A patent/EP3698788A1/en not_active Withdrawn
- 2011-08-19 AR ARP110103045A patent/AR083246A1/es not_active Application Discontinuation
- 2011-08-19 MY MYPI2013000145A patent/MY160110A/en unknown
- 2011-08-19 PL PL11818237T patent/PL2606886T3/pl unknown
- 2011-08-19 ES ES11818237T patent/ES2769550T3/es active Active
-
2012
- 2012-12-26 IL IL223892A patent/IL223892B/en active IP Right Grant
-
2013
- 2013-01-02 ZA ZA2013/00020A patent/ZA201300020B/en unknown
- 2013-06-20 HK HK13107223.9A patent/HK1179878A1/zh unknown
-
2016
- 2016-05-11 US US15/151,601 patent/US10646468B2/en active Active
-
2020
- 2020-04-07 US US16/842,023 patent/US20210052550A1/en not_active Abandoned
-
2021
- 2021-10-28 AR ARP210102994A patent/AR125013A2/es unknown
-
2022
- 2022-12-14 US US18/081,390 patent/US20230398096A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013001989A (es) | Composicion que comprende compuestos tetraciclicos. | |
MX2010009163A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211. | |
RU2585622C3 (ru) | Тетрациклические соединения | |
WO2010084115A3 (en) | Antiviral agents | |
MX2009010878A (es) | Pastilla de melatonina y metodos de preparacion y uso. | |
MX352480B (es) | Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina. | |
MX2009002735A (es) | Derivados de oxindol como agentes anticancerigenos. | |
GEP20146060B (en) | Pyridyl inhibitors of hedgehog signalling | |
MY159327A (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
IN2012DN03182A (es) | ||
MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
UA99787C2 (en) | Lactams as beta secretase inhibitors | |
GEP20156346B (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
MX2010013310A (es) | Derivados de heterociclil urea para el tratamiento de infecciones bacterianas. | |
MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
MX2012007590A (es) | Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. | |
IL209270A (en) | Compounds containing tricyclic nitrogen and their use as antibacterial | |
AU2010275640A8 (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
MX2012007225A (es) | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. | |
WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
GEP20135818B (en) | Nitrogenated derivatives of pancratistatin | |
GEP20146067B (en) | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD | Licence granted | ||
FG | Grant or registration |